Sirolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomalies
Phase 1
- Conditions
- ymphangiomatosis, Gorham-Stout disease and vascular anomalies
- Registration Number
- JPRN-UMIN000016580
- Lead Sponsor
- Gifu university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Allergy of sirolimus
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of clinical symptoms at 1, 3, 6, 12 after administration
- Secondary Outcome Measures
Name Time Method